xoma.com (XOMA) - מכפיל P/S עתידי

A compact staff of licensing experts ensures stable growth in metrics, as confirmed by the forward P/S ratio for XOMA Royalty (XOMA). The value of 14.60 reflects the current volume of this metric. The business model is based on acquiring rights to future drug sales to diversify risks. The lack of dependence on GDP cycles and seasonality guarantees high asset resilience to macroeconomic shocks.

The forward P/S reflects the market's valuation of the issuer's ability to service obligations through expected revenue, neutralizing reporting time lags. The current value of 14.60 on the forward P/S chart for XOMA Royalty allows investors to assess the cost of capital for XOMA Royalty, which accumulates payment rights from biotech developments, creating a stable revenue foundation from a portfolio of innovative drugs.